Car T Cell Therapy Market Targeting Cancer with Cutting-Edge Technology | Novartis AG, CARsgenTherapeutics Co., Ltd, Aurora Biopharma, Legend Biotech

Market Overview:

Car T cell therapy is a treatment in which a patient's T cells (a type of immune system cell) are modified to attack cancer cells. This therapy is still under development and shows great potential for treating certain cancers.

Market Dynamics:

The Car T cell therapy market is expected to witness significant growth owing to rising incidences of cancer across the globe. According to WHO, cancer burden rose to 19.3 million new cases and 10.0 million cancer deaths in 2020 worldwide. Moreover, greater effectiveness of Car T cell therapy over conventional treatment options for certain blood cancers such as acute lymphocytic leukemia is another factor driving its demand. Additionally, continuous advancements in Car T cell therapy development to treat various solid tumors will further support market growth over the forecast period 2023-2030.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/102

Low cost of car t cell therapy development drives the market growth

The cost of developing car t cell therapy has reduced drastically over the past few years due to advancements in research and technology. Earlier car t cell therapy treatment involved extensive research and clinical trials costing millions of dollars to develop a single treatment. However, with streamlined processes and re-usability of car t cells, the development cost has reduced to a few hundred thousand dollars. This lower cost of development has attracted more pharmaceutical and biotech companies to invest in car t cell therapy research. The reduced development cost also allows treatment of lesser prevalent cancer types which were not economically viable previously. As the cost of car t cell therapies in the market also decreases, the demand and accessibility of these life-saving treatments are expected to increase considerably over the coming years. The lower development cost has accelerated the clinical research of car t cells against various cancer types and pushed the boundaries of cell and gene therapy thereby driving growth of the overall car t cell therapy market.

Increased FDA approvals of car t cell therapies fuel market revenue

The U.S FDA has approved a rising number of car t cell therapies over the past few years for the treatment of blood cancers. For example, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) have obtained FDA approval for treatment of certain lymphomas and leukemias. Brexucabtagene autoleucel (Tecartus) has also been approved for treatment of mantle cell lymphoma recently. Several other car t cell therapy candidates are in late stage clinical trials and expected to be commercialized in the near future. This increasing FDA nods validate the clinical efficacy and safety of these novel treatment options. As more car t cell therapies receive regularity approvals, their adoption and revenue generation is poised to surge exponentially. The approval momentum encourages biotech investment in this sector and drives market forces to make these life-saving therapies accessible to more patients.

High treatment costs pose a challenge for widespread adoption

Despite the considerable benefits, car t cell therapy treatment involves substantially high costs ranging from $350,000 to $400,000 per patient in the U.S. This is due to several factors like the complex ex-vivo manufacturing process, specialized facilities required, intense healthcare resources consumed during treatment and long-term patient follow-ups. The high costs render car t cell therapy unaffordable for many and out-of-reach for patients in underdeveloped or developing regions. Even in countries with universal healthcare, the overall healthcare budgets may find it difficult to absorb the high treatment expenditure of these new therapies. The intense costs challenge the sustainable delivery and larger adoption of car t cell treatments especially in settings where affordability is a major restriction. Overcoming the financial barrier through funding avenues and cost reduction strategies is essential to unlock the mass market potential of car t cell therapy.

Emerging collaborative models present commercialization opportunities

Adoption of collaborative models in car t cell therapy commercialization can help extend the benefits of these treatments to more patient populations. Partnerships between hospitals, healthcare providers, insurers, drug makers and others can help cut costs, improve accessibility and streamline delivery. For example, academic research centers collaborating with pharmaceutical giants for mass production capabilities. Or drug makers forming alliances to pool manufacturing and supply chain resources to reduce per patient expenses. Healthcare technology firms developing digitized platforms for doctor consultations and remote patient monitoring. Such collaborative innovation models have the potential to address current challenges like high treatment costs, limited manufacturing capacities and affordability barriers. As the market matures, strategic collaborations are likely to play a bigger role in car t cell commercialization. This presents lucrative opportunities for stakeholders across the value chain to realize the vast market potential.

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/102

Increasing focus on solid tumor CAR T cell therapies points to future trends

While initial car t cell therapies gained regulatory approvals for hematological cancers, focus is increasingly shifting towards the development of car t cell treatments against various solid tumors. Challenges associated with solid tumor microenvironments are being addressed through novel technology platforms, next-gen car constructs and combination strategies. Several pharmaceutical companies have ongoing clinical trials evaluating car t cells against lung cancer, ovarian cancer, prostate cancer, breast cancer and other prevalent solid tumors.

Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, a detailed analysis of the competitive landscape, and product services of key players. Analysis of Car T Cell Therapy companies, key tactics followed by Leading Key Players:

â—˜ Bristol-Myers Squibb Company
â—˜ Johnson & Johnson Services Inc.
â—˜ Novartis AG
â—˜ CARsgenTherapeutics Co. Ltd
â—˜ Aurora Biopharma
â—˜ Legend Biotech
â—˜ Gilead Sciences Inc.
â—˜ Pfizer Inc.
â—˜ bluebird bio Inc.
â—˜ Sorrento Therapeutics Inc.
â—˜ Mustang Bio
â—˜ Fate Therapeutics

Note: Major Players are sorted in no particular order.

By Targeted Antigen:

CD19
BCMA
HER2
GD2
CD20
CD22
CD30
CD33
HER1
Others (CLDN18, etc.)

By Therapeutic Application:

Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Diffuse Large B-cell Lymphoma (DLBCL)
Follicular Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Glioblastoma
Sarcoma
Neuroblastoma
Acute Myeloid Leukemia
Breast Cancer
Pancreatic Cancer
Hepatocellular Carcinoma
Colorectal Cancer
Others (Gastric Cancer, etc.)

The Study Objectives are:

A comprehensive insight into key players operating in the Car T Cell Therapy Market and their corresponding data.
It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
Regional analysis, which includes insight into the dominant market and corresponding market share.
It also includes various socio-economic factors affecting the evolution of the market in the region.
The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.
Table of Contents:

Market scenario 2023

Chapter 1: Introduction, Market Driving Force Product Objective of Study and Research Scope the Car T Cell Therapy market
Chapter 2: Exclusive Summary - the basic information of the Car T Cell Therapy Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends, and Challenges & Opportunities of the Car T Cell Therapy
Chapter 4: Presenting the Car T Cell Therapy Market Factor Analysis, Supply/Value Chain, PESTEL analysis, Market Entry, and Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User, and Region/Country 2023 - 2030
Chapter 6: Evaluating the leading manufacturers of the Car T Cell Therapy market which consists of its Competitive Landscape, Peer Group Analysis, Market positioning & Company Profile
Chapter 7: To evaluate the market by segments, by countries, and by Manufacturers/Companies with revenue share and sales by key countries in these various regions (2023-2030)
Chapters 8 & 9: Displaying the Appendix, Methodology, and Data Source

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/102

Key Questions Answered:

What is the market size and CAGR of the Car T Cell Therapy Market during the forecast period?
How is the growing demand impacting the growth of Car T Cell Therapy Market shares?
What is the growing demand of the Market during the forecast period?
Who are the leading vendors in the market and what are their market shares?
What is the impact of the COVID-19 pandemic on the APAC Car T Cell Therapy Market?

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.